Idioma:

Preclinical Studies of Pegylated- and Non-Pegylated Liposomal Forms of Doxorubicin as Radiosensitizer on Orthotopic High-Grade Glioma Xenografts

Chastagner, P. ; Sudour, H. ; Mriouah, J. ; Barberi-Heyob, M. ; Bernier-Chastagner, V. ; Pinel, S.

Pharmaceutical research, 2015, Vol.32 (1), p.158-166 [Periódico revisado por pares]

Boston: Springer US

Texto completo disponível

Citações Citado por

Enviar para

Título:
Preclinical Studies of Pegylated- and Non-Pegylated Liposomal Forms of Doxorubicin as Radiosensitizer on Orthotopic High-Grade Glioma Xenografts
Autor: Chastagner, P. ; Sudour, H. ; Mriouah, J. ; Barberi-Heyob, M. ; Bernier-Chastagner, V. ; Pinel, S.
Assuntos: Animals ; Biochemistry ; Biomedical and Life Sciences ; Biomedical Engineering and Bioengineering ; Biomedicine ; Brain cancer ; Brain Neoplasms - drug therapy ; Brain Neoplasms - metabolism ; Brain Neoplasms - radiotherapy ; Cancer ; Cell Line, Tumor ; Dose-Response Relationship, Drug ; Doxorubicin - administration & dosage ; Doxorubicin - analogs & derivatives ; Doxorubicin - pharmacokinetics ; Doxorubicin - therapeutic use ; Doxorubicin - toxicity ; Drug Administration Schedule ; Drug delivery systems ; Female ; Glioma - drug therapy ; Glioma - metabolism ; Glioma - radiotherapy ; Humans ; Life Sciences ; Medical Law ; Mice, Nude ; Neoplasm Grading ; Pharmaceutical sciences ; Pharmacology/Toxicology ; Pharmacy ; Polyethylene Glycols - administration & dosage ; Polyethylene Glycols - pharmacokinetics ; Polyethylene Glycols - therapeutic use ; Polyethylene Glycols - toxicity ; Radiation therapy ; Radiation-Sensitizing Agents - administration & dosage ; Radiation-Sensitizing Agents - pharmacokinetics ; Radiation-Sensitizing Agents - therapeutic use ; Radiation-Sensitizing Agents - toxicity ; Research Paper ; Tissue Distribution ; Treatment Outcome ; Xenograft Model Antitumor Assays
É parte de: Pharmaceutical research, 2015, Vol.32 (1), p.158-166
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Purpose Free doxorubicin (DXR) is not currently used to treat brain tumors because (i) the blood–brain barrier limits the drug deposition into the brain (ii) lethal toxic effects occur when combined with radiation therapy. Since encapsulation of DXR within liposomal carriers could overcome these drawbacks, the present study aimed at evaluating the radiosensitizing properties of non-pegylated (NPL-DXR) and pegylated (PL-DXR) liposomal doxorubicin on orthotopic high-grade glioma xenografts (U87). Methods DXR accumulation in brain tissues was assessed by a high-performance liquid chromatography method and antitumor efficacy was evaluated by mice survival determination. Results We showed that encapsulation of DXR ensured a preferential deposition of DXR in tumoral tissue in comparison with normal brain tissue: the best AUC tumor tissue/AUC normal tissue ratio depended greatly on the schedule. Overall, thanks to the optimization of the delivery schedule, we demonstrated a radiosensitizing effect for both liposomal DXR without toxicity of this combination on the U87 human malignant glioma orthotopic xenografts. Conclusion This study shows that the use of nanocarriers, allowing targeting of intracerebral tumor, renders relevant the combination of anthracyclin with radiation therapy to treat brain tumors, opening a new field of therapeutic applications. However, our results point out that, for each new delivery system, the administration schedules need to be rigorously optimized.
Editor: Boston: Springer US
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Preclinical Studies of Pegylated- and Non-Pegylated Liposomal Forms of Doxorubicin as Radiosensitizer on Orthotopic High-Grade Glioma Xenografts

Chastagner, P. ; Sudour, H. ; Mriouah, J. ; Barberi-Heyob, M. ; Bernier-Chastagner, V. ; Pinel, S.

Boston: Springer US

Buscando em bases de dados remotas. Favor aguardar.